Market Data
Market Cap₹2,578.3 Cr.
52W High₹306.75
Current Price₹164.45
52W Low₹129
Down from 52W High46.4 %
Face Value₹2
Performance
ROCE1.94 %
ROE0.24 %
EPS (TTM)₹-3.69
EPS Prev Qtr₹1.39
EPS Last Year₹4.16
EBITDA Qtr₹-30.6 Cr.
Book Value₹422
Financial Health
Debt/Equity0.42
Debt/Profit171.75
Total Assets₹11,923.31 Cr.
Promoter Holding59.32 %
Earning Power1.15 %
Valuation
Stock P/E159.66
Industry P/E33.81
Price to Book0.39
Price to Sales0.89
Graham Number₹98.85
Key Metrics
Debt/Equity
0.48
__derived
1
Face Value
₹2
Interest Coverage
0.85
About Dishman Carbogen Amcis Ltd
Healthcare · Pharmaceuticals
Dishman Carbogen Amcis Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹2,578.3 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company maintains a healthy promoter holding of 59.32%, indicating strong control and alignment of interests.
- The P/B ratio is 0.47, suggesting the stock may be undervalued relative to its book value.
Weaknesses
- The P/E ratio of 169.32 indicates the stock is significantly overvalued relative to earnings.
- ROCE of 2.32% shows poor return on capital employed, reflecting inefficient use of assets.
- ROE of 0.28% is extremely low, indicating weak profitability relative to shareholder equity.
- Interest coverage ratio of 0.85 is below 1, suggesting potential difficulty in meeting interest obligations.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue fell 4.3% YoY, Profit fell 347.2% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 708.05 | 652.65 | 719.8 | 851.4 | 677.64 |
| ↳ QoQ Growth | - | -7.8% | +10.3% | +18.3% | -20.4% |
| Expenses | 648.72 | 587.89 | 691.11 | 777.24 | 708.24 |
| Operating Profit | 59.33 | 64.76 | 28.69 | 74.16 | -30.6 |
| OPM % | 8.38% | 9.92% | 3.99% | 8.71% | -4.52% |
| Other Income | 24.75 | 8.11 | 6.66 | 16.42 | 18.16 |
| Interest | 42.76 | 42.33 | 45.79 | 43.3 | 37.09 |
| Depreciation | 81.35 | 84.13 | 84.42 | 88.79 | 90.68 |
| EBITDA | 140.68 | 148.89 | 113.11 | 162.95 | 60.08 |
| EBITDA Margin % | 19.87% | 22.81% | 15.71% | 19.14% | 8.87% |
| Profit Before Tax | 38.67 | 30.54 | -10.44 | 46.13 | -51.22 |
| Tax % | 39.46% | -113.72% | -24.23% | 52.87% | -13% |
| Net Profit | 23.41 | 65.27 | -12.97 | 21.74 | -57.88 |
| ↳ QoQ Growth | - | +178.8% | -119.9% | +267.6% | -366.2% |
| EPS | 1.5 | 4.16 | -0.83 | 1.39 | -3.69 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 2931.9 | 2901.49 |
| Expenses | 2704.96 | 2764.48 |
| Operating Profit | 226.94 | 137.01 |
| OPM % | 7.74% | 4.72% |
| Other Income | 55.94 | 49.35 |
| Interest | 174.18 | 168.51 |
| Depreciation | 338.69 | 348.02 |
| Profit Before Tax | 104.9 | 15.01 |
| Tax % | 7.1% | -7.66% |
| Net Profit | 97.45 | 16.16 |
| EPS | 6.22 | 1.03 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
-38.67%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
0.24%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 31.36 | 31.36 |
| Reserves | 5800.16 | 6645.54 |
| Borrowings | 2388.95 | 2775.4 |
| Other Liabilities | 1778.68 | 2471.01 |
| Total Liabilities | 9999.15 | 11923.31 |
| Fixed Assets | 2923.53 | 8366.31 |
| CWIP | 251.69 | 275 |
| Investments | 97.39 | 96.01 |
| Other Assets | 6726.54 | 3185.99 |
| Total Assets | 9999.15 | 11923.31 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 375.23 |
| Cash from Investing Activity | -192.21 |
| Cash from Financing Activity | -102.09 |
| Net Cash Flow | 80.93 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 1138.85 |
| ROCE % | 2.48% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 59.32% | 59.32% | 59.32% | 59.32% |
| FIIs % | 8.07% | 7.66% | 7.45% | 6.86% |
| DIIs % | 1.37% | 1.27% | 1.63% | 2.06% |
| Public % | 26.84% | 27.31% | 27.2% | 27.32% |
| No. of Shareholders | 49,455 | 48,481 | 49,009 | 49,430 |
Major Shareholders (>1%)
- Adimans Technologies LlpPromoter and Promoter Group59.32%
- Mukul Mahavir AgrawalPublic Shareholding5.50%
- Massachusetts Institute Of TechnologyPublic Shareholding2.28%
- Hbm Healthcare Investments (cayman) LtdPublic Shareholding2.19%
As of 2026-06-30View all shareholders →